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Abstract  43 
Background 44 
PCA3 is a long non-coding RNA (lncRNA) with unknown function, upregulated in 45 
prostate cancer. LncRNAs may be processed into smaller active species. We 46 
hypothesized this role for PCA3 and searched for small transcribed RNAs within 47 
this gene locus. 48 
 49 
Methods 50 
We computed energetically feasible RNA hairpins within the BMCC1 gene locus 51 
(encompassing PCA3). We searched a deep-sequencing prostate transcriptome 52 
for RNAs derived from these hairpins. We measured their expression using 53 
QrtPCR in three cohorts of prostate cancer tissues (n=60), exfoliated urinary 54 
cells (n=484 with cancer and n=166 controls) and in cell lines (n=22). We used in 55 
silico predictions and RNA knock-up to identify potential mRNA targets of short 56 
transcribed RNAs. 57 
 58 
Results 59 
We predicted 13 hairpins, of which PCA3-shRNA2 was most abundant within the 60 
prostate transcriptome. PCA3-shRNA2 is located within intron 1 of PCA3 and 61 
appears regulated by androgens. Expression of PCA3-shRNA2 was upregulated 62 
in malignant prostatic tissues, exfoliated urinary cells from men with prostate 63 
cancer (13-273 fold change, T Test p<0.003) and closely correlated to PCA3 64 
expression (r=0.84 to 0.93, p<0.001). Urinary PCA3-shRNA2 (C-index 0.75-0.81) 65 
and PCA3 (C-index 0.78) could predict the presence of cancer in most men. 66 
PCA3-shRNA2 knock-up altered the expression of predicted target mRNAs, 67 
  
including COPS2, SOX11, WDR48, TEAD1 and Noggin. PCA3-shRNA2 expression 68 
was negatively correlated with COPS2 in patient samples (r=-0.32, p<0.001). 69 
 70 
Conclusion 71 
We identified a short RNA transcribed from the PCA3 gene, whose expression is 72 
closely correlated to PCA3, which may target mRNAs implicated in prostate 73 
biology. 74 
 75 
Impact 76 
This short RNA is stable ex vivo, suggesting a role as a more robust target of the 77 
PCA3 assay. We identify cytoplasmic enrichment of this RNA and potential 78 
targeting of mRNAs implicated in prostate carcinogenesis. 79 
 80 
  81 
  
Introduction 82 
Prostate cancer (PCa) is the most common cancer in men (1). The diagnosis of 83 
PCa is typically based on a combination of digital rectal examination (DRE), 84 
serum PSA and prostate biopsy (2). This approach leads to over diagnosis of 85 
indolent cancer and can delay the detection of significant disease. Non-protein 86 
biomarkers have been identified to help this diagnostic approach. To date, 87 
Prostate Cancer Associated 3 (PCA3) appears the most promising and received 88 
FDA approval in 2012 (3). The diagnostic assay (PROGENSATM) uses quantitative 89 
rtPCR to measure the expression of the PCA3 and PSA mRNA in post-prostatic 90 
massage urine samples (4). The PCA3 score (PCA3/PSA mRNA ratio x 1000) is 91 
higher in men with PCa than in controls and may be used to guide the need for 92 
further prostate biopsy (5, 6). 93 
  94 
PCA3 is a long non-coding RNA (lncRNA) that is over-expressed in most PCa 95 
specimens. The PCA3 gene is located on chromosome 9q21-22 in an antisense 96 
orientation within intron 6 of the BMCC1/PRUNE2 gene (7)(8). PCA3 expression 97 
is predominantly restricted to the prostate, under androgen regulation and the 98 
gene may produce multiple transcripts through splicing and alternate 99 
polyadenylation (8). The adoption of PCA3 assay into clinical practice has been 100 
hampered by several factors. Firstly, the assay detects a lncRNA (gene length 101 
25kb, PCR target sequence is 380 bases) that is unstable ex vivo. Target 102 
transcripts require protection from RNAses prior to analysis, making the test 103 
expensive and vulnerable to transportation errors. Secondly, the function of 104 
PCA3 is unknown, producing a biological gap in knowledge. Finally, the test has a 105 
  
poor sensitivity for PCa and is mainly used in conjunction with serum PSA in 106 
men with a previous negative biopsy (5). 107 
 108 
The importance of lncRNAs in human health and disease is becoming clearer (9) 109 
(10). The GENCODE consortium recently annotated 9,277 lncRNA genes, 110 
corresponding to 14,880 transcripts (11). In contrast to protein coding genes, 111 
lncRNAs typically have few gene exons, can be processed into active short 112 
species (12, 13)(14) and are not conserved from primitive species (15). As no 113 
functional role for PCA3 has been assigned to date, we wondered whether this 114 
ncRNA might encode an active shorter species. To test this hypothesis, we 115 
searched for possible short ncRNAs derived from sequence within the 116 
boundaries of the BMCC1 primary transcript, which spans PCA3, and evaluated 117 
their translational role. Here we report the outcomes of this work. 118 
 119 
 120 
Materials and Methods 121 
Identification of hairpin RNA structures 122 
To identify short potentially transcribed ncRNAs, we searched the BMCC1 gene 123 
locus for predicted and energetically feasible RNA hairpins using ProMir II (16) 124 
and MiPred (17). These programs compare random sequences within the target 125 
hairpin using structure-sequence composition and minimum of free energy of 126 
the secondary structure. We then searched a small RNA transcriptome generated 127 
from malignant prostatic epithelium using deep sequencing (18) for RNA 128 
sequences derived from these predicted hairpins. We measured the expression 129 
of any identified short RNA sequences using custom stem loop primers (TaqMan 130 
  
small RNA assays, Applied Biosystems, UK) with realtime qPCR (as described 131 
(19)) in cell lines and human tissues samples. 132 
 133 
Cell lines and androgen regulation of RNA 134 
We examined a panel of cell lines representing prostate cancer (DU145, LNCap, 135 
LNCap-LN3, LNCaP-pro5, PC2, PC3M, PC3M-ln4) and other common human 136 
malignancies (A549 and NCI-H460 (lung), AN3CA (endometrial), EJ/T24, RT112 137 
and RT4 (bladder), HCT-116 (colorectal), HEK293 (human embryonic kidney), 138 
HeLa (Vulval), Jurkat (T-Cell lymphoma), MCF-7 and T47D (breast), MRC5 (lung 139 
fibroblasts), SKOV-3 (ovarian) and WM793 (melanoma)). Cell lines were grown 140 
in appropriate media according to standard methods (20). To determine 141 
androgen regulation of candidate RNAs, we examined their expression in LNCap 142 
cells (chosen for their androgen dependency) growing in androgen-depleted 143 
media (phenol red free RPMI-1640 and 10% charcoal stripped serum (Sigma)) 144 
with no (0nM), 1nM and 10nM added testosterone (7).  145 
 146 
Expression in Prostatic RNA  147 
We measured the expression of candidate short RNAs in prostatic tissues and 148 
urinary samples enriched for prostatic cells and secretions. Frozen malignant 149 
and histologically benign prostatic tissues were obtained using laser-capture 150 
microdissection of fresh radical prostatectomy specimens from the University of 151 
Erlangen, Germany. Each sample was marked by a dedicated uropathologist (AH) 152 
and tissue extracted from 10 x 10uM sections (>80% tumor purity). RNA from 153 
exfoliated prostatic urinary cells and secretions was collected following vigorous 154 
prostatic massage in men with PCa and matching controls within separate pilot 155 
  
and validation cohorts from the University of Sheffield, UK. Controls were 156 
matched for age and PSA, and selected if they had undergone 2 or more prostatic 157 
biopsies without finding cancer. Following massage, the first 10-20mls of urine 158 
was collected and centrifuged. The cell pellet was then washed twice in PBS 159 
before storage. All samples were frozen at -80oC until use. Ethics committee 160 
approval was in place before commencement of this study. 161 
 162 
RNA extraction and quantification 163 
Total RNA was extracted using the mirVanaTM extraction kit (Ambion, TX) and 164 
measured using a 2100 Bioanalyzer (Agilent, Cheshire, UK) (as described 165 
elsewhere (19)). RNA expression was determined using realtime quantified 166 
rtPCR with primers for PCA3, BMCC1, PSA ((4, 7)) and two custom stem loop 167 
hairpin primers for PCA3-shRNA2 ȋ ǲaǳ  ǲbǳǣ target sequences 168 
[ACTGCACTCCAGCCTGGGCA] and [CACTGCACTCCAGCCTGGGCA] Ambion: 169 
(Assay IDs: SCSGJ090, CSHSNF8 respectively) using qrtPCR (21). Expression of 170 
PCA3, BMCC1 and PCA3-shRNA2 was normalized to PSA and fold change 171 
calculated using ȟ  (21). For RNA localization studies, we extracted 172 
separate nuclear and cytoplasmic RNA fractions from cells using standardized 173 
methodology (methods detailed in (22)).  174 
 175 
Cloning primary transcript using 3ǯ 176 
To determine the sequence (and genomic origin) of the primary RNA transcript 177 
producing our short RNA, we performed  ?ǯrapid amplification of cDNA ends 178 
(RACE) in PC3 cells using the GeneRacer kit according to manufacturers 179 
guidelines (Life technologies, UK). Briefly, total RNA was precipitated, cleaned, 180 
  
polyadenylated, adaptor ligated and amplified with hot start PCR using primers 181 
to the shRNA and the adaptor. The target sequences were cloned into E. coli 182 
(Top10, Life Technologies, UK), followed by extraction, purification and Sanger 183 
sequencing. Sequences were aligned, (Sequencher 5.1, Gene Codes))) and 184 
genomic matches were identified using BLAST (NCBI). 185 
 186 
mRNA Target analysis and RNA knock-up 187 
We identified putative target mRNAs with complementary sequences to our 188 
candidate short RNA using TargetScan (Vsn. 4.2, www.targetscan.org). We 189 
determined prostate cancer-specific expression of these mRNAs using publically 190 
available gene expression data (Arrayexpress ID: E-GEOD-8218 (23)). We 191 
analyzed cellular functions and pathway enrichment for these mRNAs with 192 
DAVID Bioinformatics Resource of identified mRNAs (24). We focused upon 193 
those with carcinogenic or prostate specific biological functions.  194 
 195 
For exploratory analysis of targeting, we examined expression of selected mRNA 196 
targets in LNCaP cells following PCA3-shRNA2 knock-up. Briefly, we transfected 197 
cells with a custom made hairpin precursor designed to generate PCA3-shRNA2, 198 
or with an equal amount of control (scrambled) RNA (both from Ambion, UK) 199 
using Lipofectamine RNAiMAX (Life Technologies, UK) (methods detailed in 200 
(21)). We determined success of transfection using qrtPCR (as described above). 201 
All assays were performed in triplicate. We measured the expression of potential 202 
targets using qrtPCR (primer sequences and reaction conditions given in 203 
supplementary table 3) in these cell lines and in the exfoliated prostatic urinary 204 
cells from cohort 2.  205 
  
 206 
Statistical analysis 207 
RNA expression was compared between cells and tissues using Studentǯs T test 208 
or ANOVA,       ǯ  within 209 
SPSS Vsn. 14.0 (SPSS Inc, Illinois)). Graphs were plotted using PRISM 6.0 210 
(GraphPad Software inc.). The ability of each RNA to detect prostate cancer was 211 
determined using concordance indices and plotted using ROC curves (25). All 212 
tests were two sided and a p value of <0.05 taken as the threshold of significance. 213 
 214 
 215 
Results  216 
Identification of expressed short RNAs sequences within PCA3 and BMCC1  217 
In Silico analysis of the BMCC1 locus identified 13 potential RNA hairpins 218 
(supplementary table 1). Each was derived from sequence within an intron of 219 
BMCC1 and most located around the PCA3 locus. MiPred classified ten of these as 220 
likely to be real. A search of the prostate transcriptome identified 5 of these 221 
RNAs, including RNA2 (which we termed PCA3-shRNA2 (short RNA number 2), 222 
supplementary figure 1a) that accounted for 72/79 (91%) of hits. PCA3-shRNA2 223 
is located within intron 1 of the PCA3 gene adjacent to a region of high species 224 
conservation (Figure 1a).  225 
 226 
Alignment of the transcriptomic sequences to the genome revealed two potential 227  ?ǯ   PCA3-shRNA2; namely ACUG and a minority member 228 
starting with CACUG (figure 1b). We designed Taqman assays to each (given that 229   ?ǯ     is vital for mRNA-targeting) and named these assays 230 
  
PCA3-shRNA2a and PCA3-shRNA2b, respectively. We measured their expression 231 
in the 22 cell lines. We detected expression of PCA3-shRNA2 in all 7 prostate and 232 
15 other cancer cell lines (figure 1c, supplementary figure 2). PCA3 and PCA3-233 
shRNA2 expression did not vary significantly with organ of origin for these cells. 234 
We normalized RNA expression to PSA mRNA, as we were keen to compare with 235 
the commercial PCA3 assay (which uses this reference gene). Expression of the 236 
target RNA was similar whether using normalized PCA3-shRNA2a or PCA3-237 
shRNA2b primers (data not shown: r=0.98, p<0.001). We identified a correlation 238 
between the expression of PCA3 mRNA and PCA3-shRNA2 (PCA3-shRNA2a 239 
assay: r=0.92, p<0.001 and PCA3-shRNA2b assay r=0.93, p<0.001), which was 240 
closer than for BMCC1 (r=0.67 for PCA3-shRNA2a and r=0.72 for PCA3-241 
shRNA2b, p<0.001).  242 
 243 
These data support our transcriptomic analysis, but do not prove our short RNA 244 
is derived from sequence within the PCA3 intron. To analyze ǡ    ?ǯ245 
RACE to clone the primary transcript from the PCA3-shRNA2a primer. 246 
Sequenced RACE products from selected colonies aligned to the PCA3 intronic 247 
locus and supported our in silico prediction of a 98bp hairpin (red box, figure 248 
1d). A BLAST search of this 98bp sequence revealed strong (97%) homology for 249 
only one locus in the genome, i.e. that within PCA3 intron 1 (supplementary 250 
figure 1b).  251 
 252 
It is known that many RNAs important in prostate carcinogenesis are regulated 253 
by the androgen receptor. In LNCap cells (chosen for their androgen 254 
dependency), both PCA3 (2.1 ± 0.31 fold change (mean±st. dev.)) and PCA3-255 
  
shRNA2 (2.75 ± 0.23 fold change (mean±st. dev.)) were upregulated in a dose 256 
dependent manner (supplementary figure 3) by testosterone. The changes were 257 
less than seen for PSA (219.0±25.2 fold upregulation (mean±st. dev.)). 258 
 259 
Expression of PCA3-shRNA2 in prostate tissue 260 
Having identified the existence and origin of this short RNA, we investigated its 261 
expression in malignant and benign prostatic tissues from 60 radical 262 
prostatectomy specimens (Table 1, Figure 1e). We identified that expression of 263 
PCA3 and PCA3-shRNA2 were correlated (r=0.88, p<0.001) and upregulation of 264 
each RNA in malignant tissues when compared with benign samples. The extent 265 
of this difference was largest for PSA (8.6±1.2 fold change (mean±st. dev.)) and 266 
least for PCA3-shRNA2 (1.4±1 data not shown). When normalized to PSA, we 267 
found significant differences in expression for PCA3-shRNA2, PCA3 and BMCC1 268 
between malignant and benign tissues (T test p<0.01, and supplementary figure 269 
4). Once again there was close correlation in the detection of PCA3-shRNA2 270 
using PCA3-shRNA2a or PCA3-shRNA2b primers (r=0.99, p<0.001). There was 271 
less correlation between PCA3-shRNA2 and BMCC1 expression (r=0.51, 272 
p<0.001). 273 
 274 
Analysis of PCA3-shRNA2 in urinary samples 275 
The clinical utility for PCA3 is a test for prostate cancer using exfoliated prostatic 276 
urinary cells. To explore this role for PCA3-shRNA2, we examined expression in 277 
179 post-DRE urinary samples (table 1) from men with (n=129) and without 278 
prostate cancer (n=50). Once again we identified close correlation between PCA3 279 
and PCA3-shRNA2 expression (figure 2a, r=0.84, p<0.001), between the two 280 
  
PCA3-shRNA2 assays (i.e. PCA3-shRNA2a Vs. PCA3-shRNA2b, r=0.95 p<0.001), 281 
and less close correlation with BMCC1 expression (r=0.30, p<0.001). Overall 282 
there was upregulation of PCA3 (86.2±53.1 fold change (mean±st. dev.)), BMCC1 283 
(2.7±0.1) and PCA3-shRNA2 (273±0.1) in specimens from men with cancer, 284 
when compared to controls (all T Test p<0.003, figure 2b). This allowed the 285 
identification of malignancy in most men, (figure 2c: concordance indices suggest 286 
that PCA3 (C-index 0.78) and PCA3-shRNA2 (C-index 0.75) had similar accuracy 287 
for cancer, and were superior to BMCC1 (C-index 0.66)). Scatterplots comparing 288 
PCA3 with PCA3-shRNA2 expression (figures 1e and 2a) suggested less variation 289 
in malignant samples than benign samples. Thus we plotted RNA expression in 290 
the frozen tissues and urinary samples according to cancer presence 291 
(supplementary figure 5) and saw less variation for malignant (r=0.90, p<0.001) 292 
than for benign (r=0.58, p<0.001) samples. 293 
 294 
To explore the robustness of these findings, we examined a separate larger 295 
validation cohort of 471 urinary samples (figure 3). Samples were collected and 296 
processed in a similar manner to the pilot cohort. Quantitative analysis revealed 297 
PCA3-shRNA2 expression was higher in samples from men with prostate cancer 298 
than controls (13.0±2.8 fold upregulation (mean±st. dev.) in malignant samples, 299 
T Test p<0.001, supplementary figure 6). Expression of PCA3-shRNA2 did not 300 
vary with tumor stage (figure 3b), as reported for PCA3 (4), but could correctly 301 
identify PCa (C-index 0.81, figure 3c), supporting our pilot exploration outcomes.  302 
 303 
The functional role of PCA3-shRNA2 304 
  
To date, little is known about the function of PCA3. To explore a functional role 305 
for PCA3-shRNA2, we investigated its cellular localization. QrtPCR of total and 306 
nuclear fractions revealed a cytoplasmic enrichment (Nuclear:Cytoplasmic ratio 307 
=0.6) for PCA3-shRNA2, close to that seen for established microRNAs 308 
(supplementary figure 7), and very different from PCA3 (with its mostly nuclear 309 
localization). As this suggests a potential mRNA targeting capacity, we searched 310 
the genome for complementary sequences. Using TargetScan we identified 178 311 
mRNAs with complementary seed sequences (supplementary table 2). Gene 312 
enrichment analysis revealed significant associations (Bonferroni adjusted 313 
p<0.05) with pathways important for cell regulation (such as cell adhesion and 314 
growth, cell signaling) and prostate biology (such as response to steroids, TGF-Ⱦ315 
signaling and urogenital development). We annotated these mRNAs with their 316 
expression in human prostate cancer samples (23), and preferentially selected 317 
those known to be down-regulated in cancer (reflecting our hypothesized 318 
targeting by upregulated PCA3-shRNA2: defined as fold change <1.0 and T Test 319 
p<0.05) or implicated in prostate cancer biology, and having high predicted 320 
binding affinity (e.g. 8-mer seed). The resultant panel (table 2) included 321 
interesting potential targets; such as ETS variant genes 1 and 5 (ETV1 and 322 
ETV5), mitogen-activated protein kinase kinase kinase 1 (MAPK31), noggin, N-323 
cadherin and TEA domain family member 1 (SV40 transcriptional enhancer 324 
factor).  325 
 326 
We transfected DU145 cells (chosen as they have low endogenous PCA3-shRNA2 327 
expression) with the PCA3-shRNA2 plasmid and a scrambled RNA sequence, and 328 
measured RNA expression of these 12 predicted targets (supplementary figure 329 
  
8a).  We identified reciprocal knock down of COPS2 (COP9 signalosome subunit 330 
2), SOX11 (sex determining region Y - box 11), WDR48, TEAD1 and Noggin, 331 
suggestive of targeting (table 2). We measured the mRNA expression of the two 332 
strongest candidates (COPS2 and SOX11) in the largest urinary sample cohort to 333 
look for biological associations in vivo. We identified reduced expression of 334 
COPS2 in the prostate cancer samples (fold change 0.29±0.5, T test p<0.001) 335 
when compared with controls, and a significant inverse correlation between the 336 
expression of COPS2 and PCA3-shRNA2 (r=-0.32, p<0.001, supplementary figure 337 
8b,c). Non-significant lower expression for SOX11 was also seen in malignant 338 
samples (fold change 0.74±1.5, p=0.08) when compared to controls and this 339 
mRNA was not significantly correlated with PCA3-shRNA2 expression (r=-0.1, 340 
p=0.48). 341 
 342 
 343 
Discussion 344 
It is known that many transcribed RNAs do not encode proteins. These are 345 
termed ncRNAs and are currently best classified according to size and cellular 346 
location. Whilst a fraction of short RNAs, known as microRNAs (around 20-347 
22bps in size), have been extensively studied (14), little is known about the 348 
function of most long ncRNAs (reviewed in (9, 10)). Identified roles for longer 349 
ncRNAs include direct involvement in chromatin remodeling and androgen 350 
receptor regulation (26), and processing into shorter more-active ncRNAs. For 351 
example, many microRNAs are clustered together and derived from single 352 
primary transcripts (such as miRs-24-2/27a/23a) (27). Recently, Rogler et al. 353 
reported RNase MRP (a 268bp non-coding RNA component of mitochondrial 354 
  
RNA processing endoribonuclease) was the source for two short (around 20bp) 355 
RNAs important in the biology of cartilageȂhair hypoplasia (13). As such, we 356 
hypothesised that one role for PCA3 could be as a source for short biologically 357 
active species.  358 
 359 
Here we present a combination of in silico and in vitro data suggesting a short 360 
RNA hairpin is produced during processing of the PCA3 primary transcript, and 361 
that this may have a biological activity. This short RNA is located within intron 1 362 
of PCA3, close to a sequence of species conservation, suggesting biological 363 
protection. Our findings have direct and indirect clinical implications. Firstly, 364 
expression of the short ncRNA appeared closely correlated with that for PCA3. 365 
This was expected, given our data suggesting the short RNA is derived from the 366 
PCA3 transcript. In contrast to long mRNAs, short ncRNAs are stable molecules 367 
and do not decay with repeated freeze thawing or prolonged storage at room 368 
temperature without RNAse inhibition. For example, we recently reported that 369 
short RNAs do not dramatically degrade with prolonged storage at room 370 
temperature (in plain clean universal containers without RNAase inhibitors) and 371 
with freeze thawing (28). As such, PCA3-shRNA2 may be a more stable 372 
biomarker for prostate cancer than PCA3. Assays to detect PCA3-shRNA2 would 373 
not be so vulnerable to delays in handling or variations in stringency in 374 
collection, and so should be more reproducible. In post-DRE urinary cell pellets 375 
from two large patient cohorts, we found that PCA3-shRNA2 detected cancer 376 
with a similar accuracy to PCA3. Whilst the PCA3 test is currently normalized to 377 
PSA mRNA expression, it is likely that short RNAs (such as prostate specific 378 
microRNAs) could replace the need for this mRNA.   379 
  
 380 
Secondly, our data suggest a potential functional role for PCA3 and derivative 381 
short RNAs. An unbiased genome-wide computational search identified genes 382 
and pathways implicated in the biology of prostate cancer. Whilst many 383 
annotated genes in these pathway enrichment datasets are implicated in cell 384 
homeostasis and regulation, relatively few are annotated for steroidal regulated 385 
pathways, TGF-Ⱦ    Ǥ As such, the 386 
identification of genes involved in these pathways is extremely pertinent and 387 
adds support for a role of PCA3-shRNA2 in prostate biology. Our preliminary 388 
targeting analysis identified changes in COPS2, SOX11, WDR48, TEAD1 and 389 
Noggin with PCA3-shRNA2 upregulation. These mRNAs play roles in the 390 
regulation of gene transcription, urogenital tract development and in cell growth 391 
and signaling. As such, they appear ideal carcinogenic gene candidates. In a 392 
further analysis we explored the expression of COPS2 and SOX11 in exfoliated 393 
urinary cell pellets.  We found that COPS2 expression was correlated to PCA3-394 
shRNA2, suggesting biological validation, and that a trend for SOX11 was also 395 
seen. COPS2 is a transcription co-repressor that underwent a four-fold loss of 396 
expression in cells with PCA3-shRNA2 knock-up. COPS2 is a component of the 397 
COP9 signalosome complex that acts to regulate the ubiquitin conjugation 398 
pathway during various cellular and developmental processes, including 399 
phosphorylation of p53 and c-jun. COPS2 is abundantly expressed in most 400 
human tissues, suggesting an important role in cellular homeostasis, and has not 401 
been studied in depth with respect to human malignancies. SOX11 is a 402 
transcription factor belonging to the SRY-related HMG-box (SOX) family. These 403 
regulate multiple biological processes, such as hematopoiesis, vasculogenesis 404 
  
and cardiogenesis during embryonic development (29), and some members are 405 
negative regulators of the WNT-beta-catenin-TCF pathway (30) which is 406 
implicated in prostate biology. To date, whilst Katoh reported reduced 407 
expression of SOX7 in PCA cells, SOX11 function and expression has not been 408 
reported in PCa. Our data now suggest the need for further analysis of our 409 
candidate target mRNAs. Of the other predicted targets, noggin appears 410 
particularly interesting. Noggin is an antagonist of bone morphogenetic proteins 411 
(BMP) (31), which has been reported to be down regulated in prostate cancer 412 
cells (32) (33). Noggin loss leads to the development of osteoblastic bone 413 
metastatses. Reversal of this loss may be used to palliate or diminish the activity 414 
of osteolytic malignant disease. 415 
 416 
In conclusion, we have found evidence of a small active RNA that is derived from 417 
the PCA3 gene locus and probably co-expressed with PCA3 ncRNA. This may be a 418 
more suitable target of the PCA3 biomarker assay and could start to identify 419 
roles for this ncRNA in prostate biology. 420 
 421 
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Tables 534 
 535 
 536 
      1. Radical 
prostatectomy 
specimens 
2. Urinary 
Pilot Cohort 
3. Urinary 
Validation 
Cohort 
  Material Tissue Disaggregated urinary cells 
 Total  60 179 471 
Benign tissue/controls    
 Total  29 50 116 
 Age     
  Median 67.0 68.3 66.2 
  St. dev. 5.5 8.9 7.2 
 PSA     
  Median 7.1 7.8 6.2 
  St. dev. 4.9 5.9 6.2 
Prostate cancer    
 Total  31 129 355 
 Stage     
  pT1-2 7 34 279 
  pT3 24 30 61 
  Metastatic 0 49 15 
  Missing 0 7 0 
 Gleason sum    
  5 0 3 0 
  6 11 54 191 
  7 6 29 125 
  8-10 14 21 31 
  Missing 0 14 8 
 Age     
  Median 67  65.1 
  St dev 5.5  7.0 
 PSA     
  Median 7.1 7.5 7.4 
  St Dev 4.9 175.1 418.9 
  0-10 17 79 248 
  11-20 12 27 64 
  >20 2 16 37 
    Missing 0 0 9 
 537 
 538 
 539 
Table 1. Patient samples analyzed in this report 540 
 541 
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Table 2. Selected Potential targets of PCA3-shRNA2 
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COPS2 COP9 constitutive photomorphogenic homolog subunit 2 1 1 0 0 0.15 1
SOX11 SRY (sex determining region Y)-box 11 1 0 0 0 0.31 1 1
WDR48 WD repeat domain 48 1 0 0 1 0.2
TEAD1 TEA domain family member 1 1 0 1 1 0.32 1
NOG Noggin 1 0 0 0 0.27 1 1 1 1 1 2
WDR1 WD repeat domain 1 1 0 0 1 0.32
INVS Inversin 1 0 0 0 0.53 1 1
CDH2 N-cadherin 1 0 0 1 1.87 1
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 1 0 0 0 0.93 1 1 1 1 1 1
ETV5 Ets variant gene 5 1 0 0 1 0.39 1
KIAA0515 KIAA0515 2 0 0 0 1.35
ETV1 Ets variant gene 1 1 0 0 0 3.2 1
  
 
 
 
 
 
 
Supplementary table 1. Predicted hairpin RNAs within PCA3 and BMCC1 
 
 
 
End(bp) BMCC1 Region Note
Free
energy
GC ratio Entropy
Promir
value
MiPred
Result
MiPred
Confidence
Freq in
Transcriptomic data
% of hits
31,365 Intron 1 -25.5 0.38 1.9508 0.0489 Pseudo 68.70% 1 1.3%
93,278 Intron 6 (downstream PCA3) Repeat, first 75 bp is AluSx (SINE/Alu) -30.8 0.45 1.97326 0.0451 Real 54.00% 72 91.1%
100,952 Intron 6 (downstream PCA3) Repeat, MER5A (DNA/MER1_type) -36.44 0.45 1.97809 0.0617 Real 66.90% 0 0.0%
105,132 Intron 6 (downstream PCA3) Conserved in 4 mammals -27 0.33 1.8797 0.0635 Real 74.20% 0 0.0%
115,526 Intron 6 (downstream PCA3) -49.7 0.3 1.85017 5.0776 Real 74.20% 0 0.0%
163,666 Intron 6 (upstream PCA3) -46.3 0.46 1.98194 1.5115 Real 68.60% 0 0.0%
176,673 Intron 6 (upstream PCA3) Repeat, MER5A (DNA/MER1_type) -37 0.46 1.99233 0.0559 Real 62.90% 0 0.0%
181,993 Intron 6 (upstream PCA3) Conserved in human dog (see the alignment in the end of the file) -28.1 0.33 1.89539 0.0742 Real 61.10% 3 3.8%
215,235 Intron 9 -30.9 0.51 1.99248 0.1165 Pseudo 50.80% 1 1.3%
236,277 Intron 9 Repeat, L1HS (LINE/L1) -34.8 0.47 1.91696 0.0531 Real 62.30% 2 2.5%
247,401 Intron 9 Repeat, Tigger4a (DNA/MER2_type) -39.2 0.38 1.95071 85.884 Real 75.80% 0 0.0%
254,347 Intron 10 Repeat, Tigger4a (DNA/MER2_type) -29.03 0.36 1.94008 0.2239 Real 80.00% 0 0.0%
268,339 Intron 12 -27.85 0.39 1.9288 0.6003 Pseudo 51.20% 0 0.0%
  
Supplementary table 2. Predicted mRNA targets for PCA3-shRNA2 
 
Gene ID Gene name 
KIAA0515 KIAA0515 
COPS2 
COP9 constitutive photomorphogenic homolog subunit 2 
(Arabidopsis) 
AFF3 AF4/FMR2 family, member 3 
SFRS2 splicing factor, arginine/serine-rich 2 
TEAD1 
TEA domain family member 1 (SV40 transcriptional enhancer 
factor) 
ANKHD1-
EIF4EBP3 
ANKHD1-EIF4EBP3 
ANKRD57 ankyrin repeat domain 57 
BTBD3 BTB (POZ) domain containing 3 
C13orf36 chromosome 13 open reading frame 36 
C8orf33 chromosome 8 open reading frame 33 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 
CLDN22 claudin 22 
DCAKD dephospho-CoA kinase domain containing 
EIF4EBP3 eukaryotic translation initiation factor 4E binding protein 3 
ETV1 ets variant gene 1 
ETV5 ets variant gene 5 (ets-related molecule) 
FAM123A family with sequence similarity 123A 
FAM123B family with sequence similarity 123B 
FAM40B family with sequence similarity 40, member B 
FLJ20309 hypothetical protein FLJ20309 
HDHD2 haloacid dehalogenase-like hydrolase domain containing 2 
INVS inversin 
IRF2BP2 interferon regulatory factor 2 binding protein 2 
LIN9 lin-9 homolog (C. elegans) 
LMNB1 lamin B1 
LSM11 LSM11, U7 small nuclear RNA associated 
MAP3K1 mitogen-activated protein kinase kinase kinase 1 
METTL8 methyltransferase like 8 
MLLT6 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 6 
NOG noggin 
ODZ4 odz, odd Oz/ten-m homolog 4 (Drosophila) 
ORMDL1 ORM1-like 1 (S. cerevisiae) 
P15RS cyclin-dependent kinase 2B-inhibitor-related protein 
PDS5A PDS5, regulator of cohesion maintenance, homolog A (S. cerevisiae) 
PHF21A PHD finger protein 21A 
PHKA2 phosphorylase kinase, alpha 2 (liver) 
PIGA 
phosphatidylinositol glycan anchor biosynthesis, class A 
(paroxysmal nocturnal hemoglobinuria) 
PNMA1 paraneoplastic antigen MA1 
  
PSCDBP pleckstrin homology, Sec7 and coiled-coil domains, binding protein 
PXMP4 peroxisomal membrane protein 4, 24kDa 
RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 
RNF169 ring finger protein 169 
SESN2 sestrin 2 
SFRS12IP1 SFRS12-interacting protein 1 
SFRS2B splicing factor, arginine/serine-rich 2B 
SFRS3 splicing factor, arginine/serine-rich 3 
SOX11 SRY (sex determining region Y)-box 11 
SSR1 
signal sequence receptor, alpha (translocon-associated protein 
alpha) 
TLR4 toll-like receptor 4 
TYW3 tRNA-yW synthesizing protein 3 homolog (S. cerevisiae) 
WDR1 WD repeat domain 1 
WDR48 WD repeat domain 48 
XPO7 exportin 7 
ZC3H10 zinc finger CCCH-type containing 10 
ZFAND6 zinc finger, AN1-type domain 6 
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C 
LIN54 lin-54 homolog (C. elegans) 
SPTBN1 spectrin, beta, non-erythrocytic 1 
ABI1 abl-interactor 1 
ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 
ANKH ankylosis, progressive homolog (mouse) 
APH1A anterior pharynx defective 1 homolog A (C. elegans) 
ARL5B ADP-ribosylation factor-like 5B 
BRPF1 bromodomain and PHD finger containing, 1 
CCNL2 cyclin L2 
CPEB2 cytoplasmic polyadenylation element binding protein 2 
CROP cisplatin resistance-associated overexpressed protein 
CTBP2 C-terminal binding protein 2 
DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
EHMT1 euchromatic histone-lysine N-methyltransferase 1 
EIF3J eukaryotic translation initiation factor 3, subunit J 
EIF4G3 eukaryotic translation initiation factor 4 gamma, 3 
EML1 echinoderm microtubule associated protein like 1 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 
GATAD2A GATA zinc finger domain containing 2A 
H3F3B H3 histone, family 3B (H3.3B) 
HMGB2 high-mobility group box 2 
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 
IKZF2 IKAROS family zinc finger 2 (Helios) 
ITCH itchy E3 ubiquitin protein ligase homolog (mouse) 
KCMF1 potassium channel modulatory factor 1 
KCNA4 
potassium voltage-gated channel, shaker-related subfamily, member 
4 
  
LHFPL4 lipoma HMGIC fusion partner-like 4 
LMO7 LIM domain 7 
LOC399947 similar to expressed sequence AI593442 
MAGI2 
membrane associated guanylate kinase, WW and PDZ domain 
containing 2 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 
MBOAT1 membrane bound O-acyltransferase domain containing 1 
MEIS1 Meis homeobox 1 
MN1 meningioma (disrupted in balanced translocation) 1 
MON2 MON2 homolog (S. cerevisiae) 
NDN necdin homolog (mouse) 
NLK nemo-like kinase 
NMNAT2 nicotinamide nucleotide adenylyltransferase 2 
OPCML opioid binding protein/cell adhesion molecule-like 
P2RY4 pyrimidinergic receptor P2Y, G-protein coupled, 4 
PAX3 paired box 3 
PBRM1 polybromo 1 
PKD2 polycystic kidney disease 2 (autosomal dominant) 
PPP1R8 protein phosphatase 1, regulatory (inhibitor) subunit 8 
PRPF40A PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) 
PRPF40B PRP40 pre-mRNA processing factor 40 homolog B (S. cerevisiae) 
PURB purine-rich element binding protein B 
RAP2C RAP2C, member of RAS oncogene family 
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 
RELT RELT tumor necrosis factor receptor 
SENP6 SUMO1/sentrin specific peptidase 6 
SLC25A1 
solute carrier family 25 (mitochondrial carrier; citrate transporter), 
member 1 
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 
SLC38A4 solute carrier family 38, member 4 
SNX22 sorting nexin 22 
SOCS5 suppressor of cytokine signaling 5 
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
THSD7A thrombospondin, type I, domain containing 7A 
TNNI1 troponin I type 1 (skeletal, slow) 
UNK unkempt homolog (Drosophila) 
USP7 ubiquitin specific peptidase 7 (herpes virus-associated) 
VEGFA vascular endothelial growth factor A 
VGLL4 vestigial like 4 (Drosophila) 
WSB2 WD repeat and SOCS box-containing 2 
ZFAND3 zinc finger, AN1-type domain 3 
ZFHX4 zinc finger homeobox 4 
ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) 
ZNF516 zinc finger protein 516 
ZNF740 zinc finger protein 740 
ZNF827 zinc finger protein 827 
  
tcag7.1228 hypothetical protein FLJ25778 
ABHD13 abhydrolase domain containing 13 
ANKS6 ankyrin repeat and sterile alpha motif domain containing 6 
ARHGEF5 Rho guanine nucleotide exchange factor (GEF) 5 
ASB8 ankyrin repeat and SOCS box-containing 8 
BLID BH3-like motif containing, cell death inducer 
BRMS1L breast cancer metastasis-suppressor 1-like 
C1orf83 chromosome 1 open reading frame 83 
C22orf15 chromosome 22 open reading frame 15 
CD84 CD84 molecule 
CEP350 centrosomal protein 350kDa 
CSDE1 cold shock domain containing E1, RNA-binding 
DCP1A DCP1 decapping enzyme homolog A (S. cerevisiae) 
DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 
DLX2 distal-less homeobox 2 
FAM104A family with sequence similarity 104, member A 
GMEB2 glucocorticoid modulatory element binding protein 2 
HAO1 hydroxyacid oxidase (glycolate oxidase) 1 
KIAA1147 KIAA1147 
KLHL20 kelch-like 20 (Drosophila) 
LIMCH1 LIM and calponin homology domains 1 
LPCAT3 lysophosphatidylcholine acyltransferase 3 
MAF v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
MAPK1 mitogen-activated protein kinase 1 
MLLT4 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 4 
MTF1 metal-regulatory transcription factor 1 
NAV1 neuron navigator 1 
PISD phosphatidylserine decarboxylase 
RALBP1 ralA binding protein 1 
RAVER1 ribonucleoprotein, PTB-binding 1 
RPE ribulose-5-phosphate-3-epimerase 
SDC4 syndecan 4 
SDK1 sidekick homolog 1, cell adhesion molecule (chicken) 
SMAD4 SMAD family member 4 
SOCS1 suppressor of cytokine signaling 1 
SOCS6 suppressor of cytokine signaling 6 
SRGAP3 SLIT-ROBO Rho GTPase activating protein 3 
SSH2 slingshot homolog 2 (Drosophila) 
TARDBP TAR DNA binding protein 
TIAM2 T-cell lymphoma invasion and metastasis 2 
ZAK sterile alpha motif and leucine zipper containing kinase AZK 
ZNF263 zinc finger protein 263 
ZNF618 zinc finger protein 618 
 
  
  
Supplementary table 3. Primers and condition used to detect target mRNAs. 
 
 
ID Name Fwd Primer Rev Primer 
Annealing 
Temp 
Amplicon 
Size 
KIAA0515 KIAA0515  TGGCTCACCTTCGTCATCTGA TCATCCTCGGATACTGTTGGAA 60 °C 215 
COPS2 
COP9 constitutive photomorphogenic 
homolog subunit 2 (Arabidopsis) 
TTTTACGCCAGTTACATCAGTCG CTTCCCTCAAGTGCATTTTACCA 60 °C 234 
TEAD1 
TEA domain family member 1 (SV40 
transcriptional enhancer factor) 
GGCCGGGAATGATTCAAACAG CAATGGAGCGACCTTGCCA 60 °C 165 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) TCAGGCGTCTGTAGAGGCTT ATGCACATCCTTCGATAAGACTG 60 °C 94 
ETV1 ets variant gene 1 TGGCAGTTTTTGGTAGCTCTTC CGGAGTGAACGGCTAAGTTTATC 60 °C 170 
ETV5 ets variant gene 5 (ets-related molecule) CAGTCAACTTCAAGAGGCTTGG TGCTCATGGCTACAAGACGAC 60 °C 168 
INVS inversin TGCTCTACAGAGGCTCATCGT ACGCAATACATAAGTGGTGTTCT 60 °C 84 
MAP3K1 
mitogen-activated protein kinase kinase 
kinase 1 
TCTCACCATATAGCCCTGAGGA AGGAAAGAGTTAGGCCCTATCTG 60 °C 97 
NOG noggin CCATGCCGAGCGAGATCAAA TCGGAAATGATGGGGTACTGG 60 °C 337 
SOX11 SRY (sex determining region Y)-box 11 AGGATTTGGATTCGTTCAGCG AGGTCGGAGAAGTTCGCCT 60 °C 121 
WDR1 WD repeat domain 1 TGGGATTTACGCAATTAGTTGGA CCAGATAGTTGATGTACCCGGAC 60 °C 209 
WDR48 WD repeat domain 48 TGGGACAATTCGCCTTTGGTC TGTCAGGGTTTCTTAGGTCTGT 60 °C 164 
  
Figure legends 
 
Figure 1. Identification of PCA3 shRNA2. (a). Our potential shRNA is located in 
exon 6 of the BMCC1 gene. The Location of PCA3-shRNA2 is adjacent to a region 
of high conservation within intron 1 of PCA3. (b). Prostate cancer RNA 
transcriptomic data identified a relative abundance of this RNA. (c). Expression 
of PCA3-shRNA2 is closely correlated with PCA3 and less so to BMCC1 (DCT Ȍ ǤȋȌǤ  ?ǯ
identifies the longer hairpin structure in LNCap cells. (e). Expression of PCA3-
shRNA2 is closely correlated with PCA3 in frozen benign and malignant prostatic 
tissues. 
 
 
Figure 2. Expression of PCA3, BMCC1 and PCA3-shRNA2 in the urinary RNA 
from men with and without prostate cancer. (a). Expression of PCA3-shRNA 
was closely correlated with PCA3 expression (r=0.84). (b). Expression was 
higher in urinary pellets from men with prostate cancer than in benign controls 
for each RNA. (c). Expression of each RNA could identify the presence of the 
disease in most men. In comparison, PC3 and PCA3-shRNA2 expression were 
more reliable (c-indices 0.78, 0.75, respectively) than BMCC1 (c-index 0.66). 
 
 
Figure 3. Detection of prostate cancer using PCA3-shRNA2. (a). Expression of 
PCA3-shRNA was correlated with PCA3 expression. (b). Expression was higher in 
urinary pellets from men with prostate cancer (Pca) than in benign controls, but 
did not vary with cancer stage (ANOVA p=0.46 between stages) (c). Expression 
could identify the presence of the disease in most men (C-index 0.81). 
 
 
 
  
  
Supplementary Figure 1. Identification of the PCA3-shRNA2 hairpin. (a). 
Predicted hairpin of PCA3 RNA2. The bases in red are those identified within the 
prostate RNA transcriptome. (b). BLAST results of the 98bp fragment derived 
from PCA3- ?   ?ǯǡ       n 
PCA3 intron 1. 
 
Supplementary figure 2. Expression of PCA3 and PCA3-shRNA2 in cell lines 
representing prostate cancer (blue and labeled) and other malignancies 
(red). The expression of the two PCA3 RNAs is shown (normalised to PSA mRNA 
expression) for each of 22 cell lines. The non-prostate cancer cell lines are not 
labeled for clarity. In order of PCA3-shRNA2 expression these are (from HCT-116 
(PCA3-shRNA2 DCt=-15.85), HEK 293, A549, NCI-H460, WM793, RT112, T47D, 
MRC5, AN3CA, RT4, SKOV-3, EJ, MCF-7, Jurkat and HeLa (PCA3-shRNA2 
DCt=5.08)). 
 
Supplementary figure 3. Androgen regulated expression of PSA, PCA3 and 
PCA3 shRNA2. Expression (fold change) was determined using qrtPCR and 
normalized to a non-androgen regulated U1 RNA. PCA3 and PCA3 shRNA 
expression was directly related to testosterone concentration within growth 
media (0, 1nM and 10nM) 
 
Supplementary figure 4. Expression of PCA3, BMCC1, PCA3-shRNA2a and 
PCA3-shRNA2b in malignant and benign prostatic tissue. Significantly higher 
expression is seen in malignant tissues, when compared to benign tissues, for 
BMCC1 (DCt: -11.5±2 vs. -14.1±3, T Test p<0.01 for malignant vs. benign) and 
PCA3-shRNA2 (e.g. PCA3-shRNA2a DCt: 2.15±5 vs. -1.17±4). 
 
Supplementary figure 5. Correlation of PCA3 and PCA3-shRNA2 in urinary 
and frozen tissue according to pathology. Expression of the two RNAs was 
closer correlation in (a). malignant than in (b). benign samples.  
 
Supplementary figure 6. Expression of PCA3-shRNA2 in the validation 
cohort of men, stratified by the presence of prostate cancer and benign 
prostatic hyperplasia.  
 
Supplementary figure 7. Expression of PCA3-shRNA2 and primary/mature 
miRs according to nuclear and cytoplasmic localization. The ratio between 
nuclear and cytoplasmic RNA normalized expression is shown for PCA3-shRNA3 
in red and various primary and mature microRNAs for comparison. For each 
mature short RNA (including PCA3-shRNA2), the majority of the transcript is 
expressed within the cytoplasm, in contrast to the primary miR hairpin 
transcript.  
 
Supplementary figure 8. PCA3-shRNA2 in DU145 and SOX11 expression. 
(a). Expression of PCA3-shRNA2 RNA in cells transfected with the correct 
sequence, mock transfection with a scrambled RNA sequence and untransfected 
cells. Bars represent the mean of three independent repeats and standard 
deviation (error bars). (b). Expression of COPS2 is lower in the urinary cells of 
  
patients with prostate cancer (PCa) when compared to controls (BPH) and is (c). 
correlated with that of PCA3-shRNA2. 
 
